• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

SUPERNUS PHARMACEUTICALS, INC.

Notes

No. Proposition For Against Abstain
1

Election of Director to hold office for the ensuing three years and until their successors have been duly elected and qualified: Frederick M. Hudson

2

Election of Director to hold office for the ensuing three years and until their successors have been duly elected and qualified: Charles W. Newhall, III

3

To approve, on a non-binding basis, the compensation paid to our named executive officers.

4

To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.

5

To consider and act upon a proposal to amend the Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan to increase the number of shares available under the plan.